Avita Medical (NASDAQ:RCEL) Stock Price Target Raised at BTIG Research

Avita Medical (NASDAQ:RCEL) had its price objective raised by BTIG Research from $15.00 to $21.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts have also issued reports about the company. TD Cowen reaffirmed a “buy” rating on shares of Avita Medical in a report on Tuesday. Lake Street Capital raised their price target on Avita Medical from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, August 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Avita Medical in a report on Monday, September 21st. Finally, Wall Street Zen upgraded Avita Medical from a “sell” rating to a “hold” rating in a research report on Sunday, August 2nd. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $13.40.

Avita Medical Price Performance

Shares of RCEL stock traded up $0.91 on Friday, hitting $16.59. 1,137,548 shares of the stock traded hands, compared to its average volume of 423,488. The company’s fifty day moving average is $12.77 and its 200 day moving average is $6.85. Avita Medical has a 1-year low of $3.22 and a 1-year high of $18.07. The company has a market capitalization of $510.64 million, a PE ratio of -14.06 and a beta of 2.03.

Avita Medical (NASDAQ:RCEL) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. The business had revenue of $26.11 million during the quarter, compared to analyst estimates of $22.35 million. As a group, equities research analysts expect that Avita Medical will post -0.98 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RCEL. Harpswell Capital Advisors LLC acquired a new stake in shares of Avita Medical in the third quarter valued at approximately $150,000. R Squared Ltd bought a new stake in shares of Avita Medical during the first quarter valued at approximately $57,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Avita Medical by 28.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company’s stock worth $191,000 after buying an additional 3,500 shares during the period. Abel Hall LLC acquired a new position in shares of Avita Medical during the first quarter worth approximately $62,000. Finally, Quantinno Capital Management LP bought a new position in Avita Medical in the 1st quarter worth approximately $83,000. 27.66% of the stock is owned by institutional investors and hedge funds.

Key Avita Medical News

Here are the key news stories impacting Avita Medical this week:

• Positive Sentiment: Raised revenue outlook: Avita lifted its full-year 2026 revenue guidance, signaling improved expectations for growth. AVITA Medical Raises Revenue Guidance
• Positive Sentiment: Q3 beat estimates: The company reported revenue of $26.11 million, above the $22.35 million analyst consensus, and a loss of $0.20 per share, narrower than the expected $0.24 loss. Another report said revenue surged 53% year over year. AVITA Medical Reports Third Quarter Results Q3 Revenue Growth
• Positive Sentiment: Analyst price target increased: BTIG Research raised its target from $15 to $21 and maintained a Buy rating, reflecting greater potential upside in its assessment. BTIG Raises Price Target
• Positive Sentiment: Medicare billing changes: A national physician payment framework and simplified billing codes for RECELL procedures are scheduled for 2027. These changes could ease billing complexity and support broader procedure adoption. Medicare Payment Framework and Billing Codes

Avita Medical Company Profile

Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on developing and commercializing therapies that use a patient’s own cells to help restore damaged skin and tissue. Its lead product is the RECELL System, an autologous cell-harvesting device designed to prepare a suspension of a patient’s skin cells at the point of care for application to wounds.

RECELL is used in the treatment of certain thermal burn wounds and other skin injuries. The system is intended to support wound healing and may reduce the amount of donor skin required for grafting by enabling clinicians to create a cell suspension from a small sample of the patient’s healthy skin.